These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36813997)

  • 1. Eye disease drug as a potential cure for COVID-19: one foot-in-the-door.
    Patel P
    Eye (Lond); 2023 Oct; 37(14):2844-2846. PubMed ID: 36813997
    [No Abstract]   [Full Text] [Related]  

  • 2. Changing drug regimen during COVID-19 pandemic lockdown: An experience from a Tertiary Eye Care Hospital as a cornea specialist.
    Gurnani B; Kaur K
    Indian J Pharmacol; 2020; 52(5):435-436. PubMed ID: 33283776
    [No Abstract]   [Full Text] [Related]  

  • 3. Correction to: Eye disease drug as a potential cure for COVID-19: one foot-in-the-door.
    Patel P
    Eye (Lond); 2023 Oct; 37(14):3052. PubMed ID: 37237233
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of COVID-19-Associated Rhino-Orbital Mucormycosis.
    Arora R; Goel R; Meher R
    JAMA Ophthalmol; 2022 May; 140(5):548. PubMed ID: 35389467
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcome of COVID-19-Associated Rhino-Orbital Mucormycosis-Reply.
    Date PS; Choksi T; Ingole AB
    JAMA Ophthalmol; 2022 May; 140(5):548-549. PubMed ID: 35389457
    [No Abstract]   [Full Text] [Related]  

  • 6. Should Immunosuppressive Therapy Be Modified During a Pandemic?
    Bouffard MA; Levy M; Lee AG; Van Stavern GP
    J Neuroophthalmol; 2021 Jun; 41(2):266-271. PubMed ID: 33999890
    [No Abstract]   [Full Text] [Related]  

  • 7. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2020 May; 36(4):199-200. PubMed ID: 32186947
    [No Abstract]   [Full Text] [Related]  

  • 8. Intractable Ocular Diseases and Treatment Progress.
    Zhang X; Li S; Tang Y; Guo Y; Gao S
    AAPS PharmSciTech; 2020 Aug; 21(6):236. PubMed ID: 32803351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interview with Paul Ashton: sustained-release drug delivery to the eye.
    Ashton P
    Ther Deliv; 2013 Mar; 4(3):297-9. PubMed ID: 23442076
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential of Lipoprotein-Based Nanoparticulate Formulations for the Treatment of Eye Diseases.
    Fukuda R; Murakami T
    Biol Pharm Bull; 2020; 43(4):596-607. PubMed ID: 32238702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chinese expert consensus on prevention and control of COVID-19 eye disease (2022)].
    Public Health Ophthalmology Branch of Chinese Preventive Medicine Association
    Zhonghua Yan Ke Za Zhi; 2022 Mar; 58(3):176-181. PubMed ID: 35280024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Agglomerations in eye ointments].
    Lerk CF; Zuurman K
    Pharm Weekbl; 1972 Mar; 107(10):173-8. PubMed ID: 5061090
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug therapy of frequently occurring eye diseases].
    Krieglstein GK
    Med Monatsschr Pharm; 1978 Jan; 1(1):12-9. PubMed ID: 756495
    [No Abstract]   [Full Text] [Related]  

  • 14. Ocular drug delivery.
    Goepferich A
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):157. PubMed ID: 26004820
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biopharmaceutics of eye drugs].
    Naumann H
    Pharmazie; 1980 Dec; 35(12):814-7. PubMed ID: 7208591
    [No Abstract]   [Full Text] [Related]  

  • 16. Ocular Therapeutics: Drug Delivery and Pharmacology.
    Dickmann L
    Mol Pharm; 2016 Sep; 13(9):2875-6. PubMed ID: 27596048
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: Comparing the effects of 2 localized treatments on bilateral eye disease.
    Kahn HA
    Invest Ophthalmol; 1974 Aug; 13(8):634-5. PubMed ID: 4841871
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging Drug Delivery Systems for Posterior Segment Disease.
    Levine D; Albini TA; Fine HF; Yeh S
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):132-135. PubMed ID: 32211902
    [No Abstract]   [Full Text] [Related]  

  • 19. [Ascorbic acid in the treatment of eye diseases].
    Mozherenkov VP; Agafonov BV
    Oftalmol Zh; 1980; 35(2):117-9. PubMed ID: 6995889
    [No Abstract]   [Full Text] [Related]  

  • 20. Ophthalmic Drug Discovery and Development.
    Gukasyan HJ; Hailu S; Karami TK
    Pharm Res; 2019 Mar; 36(5):69. PubMed ID: 30887132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.